Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival compared with pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer.
Original Article: Lurbinectedin Does Not Improve PFS in Platinum-Resistant Ovarian Cancer